Base de dados : LILACS
Pesquisa : C04.557.337.428.080.125 [Categoria DeCS]
Referências encontradas : 151 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 16 ir para página                         

  1 / 151 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1283167
Autor: Alsagaby, Suliman A; Brewis, Ian A; Vijayakumar, Rajendran; Alhumaydhi, Fahad A; Alwashmi, Ameen S; Alharbi, Naif K; Al Abdulmonem, Waleed; Premanathan, Mariappan; Pratti, Guy; Fegan, Christopher; Pepper, Christopher; Brennan, Paul.
Título: Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia
Fonte: Electron. j. biotechnol;52:1-12, July. 2021. tab, ilus, graf.
Idioma: en.
Resumo: BACKGROUND: Chronic lymphocytic leukaemia (CLL) is a neoplasm of B-cells characterized by variable prognosis. Exploring the proteome of CLL cells may provide insights into the disease. Therefore, eleven proteomics experiments were conducted on eleven primary CLL samples. RESULTS: We reported a CLL proteome consisting of 919 proteins (false discovery rate (FDR) 1%) whose identification was based on the sequencing of two or more distinct peptides (FDR of peptide sequencing 1%). Mass spectrometry-based protein identification was validated for four different proteins using Western blotting and specific antibodies in different CLL samples. Small sizes of nucleolin (~57 kDa and ~68 kDa) showed a potential association with good prognosis CLL cells (n = 8, p < 0.01). Compared with normal B-cells, CLL cells over-expressed thyroid hormone receptor-associated protein 3 (THRAP3; n = 9; p = 0.00007), which is implicated in cell proliferation; and heterochromatin protein 1-binding protein 3 (HP1BP3; n = 10; p = 0.0002), which promotes cell survival and tumourogenesis. A smaller form of HP1BP3, which may correspond to HP1BP3 isoform-2, was specifically identified in normal B-cells (n = 10; p = 0.0001). HP1BP3 and THRAP3 predicted poor prognosis of CLL (p 0.05). Consistently, THRAP3 and HP1BP3 were found to be associated with cancer-related pathways (p 0.05). CONCLUSIONS: Our findings add to the known proteome of CLL and confirm the prognostic importance of two novel cancer-associated proteins in this disease.
Descritores: Leucemia Linfocítica Crônica de Células B
Biomarcadores Tumorais/análise
-Espectrometria de Massas
Fatores de Transcrição/análise
Proteínas Nucleares/análise
Western Blotting
Cromatografia Líquida
Proteômica
Proteínas de Ligação a DNA/análise
Responsável: CL1.1 - Biblioteca Central


  2 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1142407
Autor: Chowdhury, Zachariah; Khonglah, Yookarin; Sarma, Susmita; Kalita, Pranjal.
Título: De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase
Fonte: Autops. Case Rep;11:e2020196, 2021. tab, graf.
Idioma: en.
Resumo: B-cell prolymphocytic leukemia (B-PLL) is an extremely rare disease, accounting for approximately 1% of the lymphocytic leukemias. B-PLL generally occurs in older people. It is characterized by the presence of more than 55% prolymphocytes in the peripheral blood (PB), no or minimal lymphadenopathy, massive splenomegaly, and very high white blood cell counts. The prognosis of B-PLL patients is generally poor, with a median survival of 3 years, although a subset of patients may show a prolonged survival. Herein, we report a case of a 70-year-old male with weakness, generalized lymphadenopathy, and moderate splenomegaly at the initial presentation. Hematologic examination revealed lymphocytic leukocytosis, favoring a chronic lymphoproliferative disorder (CLPD). The key to decoding the precise CLPD was a combination of the clinical profile, morphologic findings on the peripheral blood and the bone marrow, immunophenotypic analysis, and cytogenetic study. The best diagnosis proffered was a de novo chronic lymphocytic leukemia/prolymphocytic leukemia. There was no prior history of lymphoproliferative disorder or lymphocytic leukocytosis. Discriminating this entity from other lymphoproliferative disorders is crucial as the treatment and prognosis are varied compared to the other lymphoproliferative disorders. The diagnostic conundrum encountered and the incredible utility of ancillary studies in such a scenario are highlighted in this study.
Descritores: Leucemia Linfocítica Crônica de Células B
Leucemia Prolinfocítica
Leucemia Linfoide
Leucemia Prolinfocítica Tipo Células B
-Doenças Raras
Linfadenopatia
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  3 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1045598
Autor: Charles, KS; Leelah, N; Boodoo, L; Murray, DC.
Título: Ophthalmic manifestations of haematological disorders / Manifestaciones oftálmicas de trastornos hematológicos
Fonte: West Indian med. j;62(1):99-103, Jan. 2013. ilus.
Idioma: en.
Resumo: Five case histories are presented. Waldenstrom's macroglobulinaemia caused bilateral central retinal vein occlusion, proptosis was the presenting feature of retro-orbital plasmacytoma in relapsed multiple myeloma, a red painful eye was due to neovascular glaucoma in primary polycythaemia, bilateral VIth nerve palsy caused convergent squint and diplopia in meningeal relapse of acute lymphoblastic leukaemia and lymphoma of the eyelid caused complete ptosis. Interdisciplinary management is described. Ophthalmological lesions in haematological disease should be promptly recognized and managed. Collabo-ration between ophthalmology and haematology departments may be effective for palliative management.

Se presentan cinco historias de casos. La macroglobulinemia de Waldenström causó la obstrucción bilateral de la vena central de la retina; la proptosis fue la primera manifestación del plasmacitoma retro-orbital en la recaída del mieloma; un ojo enrojecido con dolor debido a un glaucoma neovascular en una policitemia primaria; la parálisis del 7mo nervio bilateral causó estrabismo convergente y diplopía en la recaída meníngea de la leucemia linfoblástica aguda; y un linfoma del párpado causó ptosis total. Se describe el tratamiento interdisciplinario. Es necesario reconocer y tratas lo antes posible las lesiones oftalmológicas en las enfermedades hematológicas. La colaboración entre los departamentos de oftalmología y hematología puede ser efectiva a la hora de buscar tratamientos paliativos.
Descritores: Policitemia Vera/complicações
Leucemia Linfocítica Crônica de Células B/complicações
Macroglobulinemia de Waldenstrom/complicações
Oftalmopatias/etiologia
Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações
Mieloma Múltiplo/complicações
-Oftalmopatias/diagnóstico por imagem
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  4 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Chauffaille, Maria de Lourdes L. F
Texto completo
Texto completo
Id: lil-434891
Autor: Nascimento, Marilia C; Yamamoto, Mioko; Rodrigues, Maria Madalena; Franco, Luciana F; Kimura, Elisa Y. S; Vasconcelos, Yuri; Oliveira, José S. R; Figueiredo, Vera L. P; Chauffaille, Maria de Lourdes L. F.
Título: CLL: chromosomal abnormalities (FISH) and their relation with clinical stage, CD38 and ZAP-70 / Leucemia linfocítica crônica: anormalidades cromossômicas e a sua relação com o estágio clínico CD38 e o ZAP-70
Fonte: Rev. bras. hematol. hemoter;28(1):5-10, jan.-mar. 2006. tab.
Idioma: en; pt.
Projeto: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Resumo: Chronic lymphocytic leukemia is the most prevalent type of leukemia in the West. It is characterized by an extremely variable clinical course. The aim of the study was to detect the most frequent chromosomal abnormalities in patients with CLL using FISH, and assess them regarding age, gender, clinical stage and CD38 and ZAP-70 expressions. We found 51.7 percent of the patients with chromosome abnormalities. The most frequent one was del 13q14 in 34.5 percent of cases. It was associated to other alterations in 17.2 percent. 17p13 deletions were found in 17.2 percent and trisomy 12 in 13.8 percent (in isolation in 6.9 percent and associated to del 13q14, in 6.9 percent of the cases). An 11q22 deletion was found in one case associated to a 13q14 deletion. To better evaluate the relationship between chromosome aberrations and other prognostic factors in CLL, two cytogenetics groups were considered: favorable (13q deletion in isolation and no alteration) and unfavorable outcomes (trisomy 12, 17p13 deletion, 11q22 deletion and two simultaneous alterations).The unfavorable alterations were more frequently seen among young individuals (<60y). There were more females (70 percent) than males in this group (p=0.04). In relation to the Binet's staging system, patients with unfavorable cytogenetic alterations, tended to be B and C stages, while in the favorable group prevailed patients in stage A. Additionally, patients with poor prognostic cytogenetics tended to express CD38 and ZAP-70 proteins.

A leucemia linfocítica crônica (LLC) é o tipo de leucemia mais prevalente no Ocidente e é caracterizada por curso clínico extremamente variável. O objetivo deste estudo foi detectar as anomalias cromossômicas mais freqüentes em pacientes com LLC, empregando a técnica FISH, e correlacioná-las com idade, sexo, estádio clínico, expressão de CD 38 e ZAP-70. Foram encontradas alterações cromossômicas em 51,7 por cento dos pacientes. A mais freqüente foi a del 13q14, observada em 34,5 por cento dos casos e que esteve associada a outras anomalias em 17,2 por cento. Deleção 17p13 foi encontrada em 17,2 por cento e trissomia 12 em 13,8 por cento (isolada em 6,9 por cento e associada à del 13q14 em 6,9 por cento). Deleção 11q22 foi observada em um caso em concomitância à del 13q14. Para melhor avaliar a relação entre alteração cromossômica e outros fatores prognósticos em LLC, dois grupos citogenéticos foram considerados: favorável (deleção 13q isolada e ausência de alterações) e desfavorável (trissomia 12, deleção 17p13, deleção 11q22 e duas anomalias simultâneas). As alterações desfavoráveis foram mais freqüentemente observadas em indivíduos jovens (<60 anos) e em mulheres (70 por cento)(p=0,04). Em relação ao sistema de estadiamento de Binet, houve tendência dos pacientes com alterações cromossômicas desfavoráveis apresenteram-se nos estágios B e C enquanto no grupo favorável prevaleceram aqueles com estágio A. Em adição, pacientes com achados citogenéticos de prognóstico desfavorável tiveram tendência a expressar proteínas CD 38 e ZAP-70.
Descritores: Leucemia Linfocítica Crônica de Células B
-Aberrações Cromossômicas
Estágio Clínico
Hibridização in Situ Fluorescente
Citogenética
ADP-Ribosil Ciclase 1
Proteína-Tirosina Quinase ZAP-70
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  5 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-950214
Autor: Guimarães, Tatiana; Plácido, Rui; Quadros, Ana Catarina; Costa, José Marques da; Pinto, Fausto J.
Título: Unexpected Mass in the Left Atrium / Massa Inesperada no Átrio Esquerdo
Fonte: Arq. bras. cardiol;111(2):226-227, Aug. 2018. graf.
Idioma: en.
Descritores: Leucemia Linfocítica Crônica de Células B/diagnóstico
Linfoma de Células B/diagnóstico
Átrios do Coração/patologia
Neoplasias Cardíacas/diagnóstico
-Biópsia
Leucemia Linfocítica Crônica de Células B/cirurgia
Linfoma de Células B/cirurgia
Angiografia Coronária
Achados Incidentais
Angiografia por Tomografia Computadorizada
Neoplasias Cardíacas/cirurgia
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  6 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-765558
Autor: Rosselli, Diego; Díaz, Carlos Eduardo; Gutiérrez, Laura.
Título: Desenlaces clínicos en hematoncología: diez años de investigaciones en Pubmed / Clinical outcomes in Hemato-Oncology: Ten year Pubmed literature review
Fonte: Rev. colomb. cancerol;19(2):95-102, abr.-jun. 2015. ilus, tab.
Idioma: es.
Resumo: Objetivo: Determinar cuáles son los desenlaces clínicos empleados en los estudios fase III de tratamiento de neoplasias hematoncológicas y qué proporción de ellos emplean supervivencia global como desenlace primario. Método: Mediante una búsqueda en Pubmed, analizar todos los experimentos clínicos aleatorios publicados en los últimos 10 años, de tratamientos de novo, en población adulta. Resultados: La búsqueda inicial arrojó 310 referencias, entre las que se seleccionaron 90 estudios clínicos. La enfermedad más estudiada fue mieloma múltiple, con 29 estudios, seguida de linfoma no Hodgkin, con 26. Las otras fueron: leucemia mieloide aguda (12), leucemia linfocítica crónica (10), leucemia mieloide crónica (8), síndromes mielodisplásicos (3) y linfoma de Hodgkin (2). En 20 estudios (22%) se empleó la supervivencia global como desenlace primario (en solo 3 de ellos alcanzó significación estadística), en 37 más (41%) se agrupó con otros desenlaces para conformar un desenlace compuesto. En 55 estudios (61%) la supervivencia global fue un desenlace secundario. Conclusiones: Aunque la supervivencia global es el estándar de oro en terapia oncológica, los desenlaces agrupados u otros, como tiempo libre de enfermedad o indicadores paraclínicos de actividad de la enfermedad, son más empleados, quizá por ser buenos predictores y requerir muestras y seguimientos menores. Su capacidad para predecir supervivencia global (en algunos casos calidad de vida) debe ser validada. Solo en las formas más agresivas de cáncer se justifica usar de rutina la supervivencia global como el desenlace primario.

Objective: To describe the clinical outcomes used in phase III studies in Hematology-Oncology malignancies, and to determine what proportion use overall survival as the primary outcome. Methods: Using a systematic literature search in PubMed, an analysis was made of phaseIII randomized clinical trials with de novo treatments of hematology-oncological neoplasias in adult populations published in the last 10 years. Results: The initial search yielded 310 references, 90 of which were finally selected. The overall survival rate was used in 20 studies (22%) as the primary outcome (in 3 of them it reached statistical significance). Grouped intermediate outcomes were used in 37 others (41%). As a secondary outcome the overall survival rate was used in 55 studies (61%). Among the intermediate outcomes used were, response rates, disease-free or relapse-free survival rates, and progression-free survival rate. Multiple myeloma was the most studied disease, with 29 studies (32%), followed by non-Hodgkin lymphoma (28%). Conclusions: Although overall survival rate is the gold standard in cancer therapy, it is not the most often used outcome. Intermediate outcomes, such as disease-free survival or biomarkers are often good predictors, and require smaller samples and less follow-up time. Nevertheless, their predictive capacity for overall survival rate (or, in some cases, quality of life) should also be assessed. The use of the overall survival rate as the routine primary outcome is only justified in the most aggressive forms of cancer.
Descritores: Linfoma não Hodgkin
Doença de Hodgkin
Leucemia Linfocítica Crônica de Células B
Leucemia Mielogênica Crônica BCR-ABL Positiva
Leucemia Mieloide Aguda
PubMed
Mieloma Múltiplo
-População
Qualidade de Vida
Terapêutica
Biomarcadores
Doença
Taxa de Sobrevida
Adulto
Menores de Idade
Métodos
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CO40.1 - Biblioteca Médica


  7 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-915118
Autor: Saaed, Hiwa K; Mahmood, Matin A; Khoshnaw, Najmaddin.
Título: Quantitative real time PCR analysis of apoptotic gene expression in chronic lymphocytic leukemia patients and their relationships with chemosensitivity
Fonte: Appl. cancer res;37:1-7, 2017. tab, ilus.
Idioma: en.
Resumo: Background: Apoptosis-related gene expression such as BCL2, and p53 has been suggested in predicting the patient response to chemo- or radiotherapy, as well as patient's survival. Methods: The aim of this study was to determine changes in BCL2 and p53 apoptosis related gene expressions in chronic lymphocytic leukemia (CLL) patients in response to different chemotherapy regimens and number of treatment courses. The study was conducted on 55 CLL patients (44 CLL and 11 CLL/SLL; small lymphocytic lymphoma) and 40 healthy individuals as control, over three-months period. The RNA was extracted by exploitation total RNA extraction kit, treated with DNAse, then cDNA was synthesized and qRT-PCR used to analyze antiapoptotic BCL2 and tumor suppresser p53 gene expressions. Results: CLL/SLL showed higher BCL2 and p53 gene expression than CLL. The patients with CLL showed three-fold increase in BCL2 gene expression compared to healthy controls (p < 0.05), and 50% decrease in p53 gene expressions (p < 0.05). BCL2 gene expression was higher, particularly, for those who were treated with higher range of treatment courses and combination of fludarabine, cyclophosphamide and rituximab (FCR) regimen. P53 gene expression reciprocally related with BCL2 and vice versa. Conclusions: In contrary to BCL2, p53 gene was extremely expressed in patients treated with chemotherapy agents, particularly after 24­30 months disease duration; suggesting a late expression of p53 during advanced stages of the disease. A proportional change in BCL2 and p53 gene expression was reported with different treatment regimens; Chlorambucil (Clb) decreased and FCR regimen increased BCL2 gene expression. Higher p53 gene expression reported with the Chlorambucil + (Chlorambucil + Prednisolone) regimen (AU)
Descritores: Leucemia Linfocítica Crônica de Células B
Leucemia
Expressão Gênica
Genes p53
Apoptose
Genes bcl-2
Quimiorradioterapia
Limites: Humanos
Masculino
Feminino
Responsável: BR30.1 - Biblioteca


  8 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-983754
Autor: Carneiro, Clívia Maria Moraes de Oliveira; Bittencourt, Maraya de Jesus Semblano; Anjos, Andressa Bocalon dos; Brito, Fernanda Cecilia de Oliveira Costa Ataide.
Título: Atypical presentation of cutaneous herpes simplex virus in a patient with chronic lymphocytic leukemia
Fonte: An. bras. dermatol;94(1):111-113, Jan.-Feb. 2019. graf.
Idioma: en.
Descritores: Leucemia Linfocítica Crônica de Células B/virologia
Simplexvirus
Herpes Simples/patologia
Imunocompetência
-Biópsia
Resultado do Tratamento
Epiderme/patologia
Herpes Simples/tratamento farmacológico
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Carta
Responsável: BR1.1 - BIREME


  9 / 151 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-837930
Autor: Brasileiro, Ana; Lencastre, André; João, Alexandre; Fidalgo, Ana.
Título: Cutaneous leukemic infiltration following varicella - a case of Wolf's isotopic response
Fonte: An. bras. dermatol;91(5,supl.1):72-75, Sept.-Oct. 2016. graf.
Idioma: en.
Resumo: Abstract Wolf's isotopic response designates the appearance of two subsequent unrelated dermatoses in the same anatomic location. We report the case of a 51-year-old man with a medical history of chronic lymphocytic leukemia without known extra-hematopoietic involvement. The patient developed a disseminated papulo-vesiculous eruption, diagnosed as varicella. Few days after recovering, an erythematous and violaceous papular dermatosis with histopathological examination compatible with leukemic infiltration appeared on the scars of previous herpetic lesions. Complete remission was obtained under systemic corticotherapy, without cutaneous recurrence or blastic transformation. Wolf's isotopic response is attributed to a localized immunologic imbalance following a certain stimulus. In this patient, herpetic infection acted as a local spur for inaugural cutaneous leukemic infiltration, with no impact on the prognosis for the underlying disease.
Descritores: Pele/patologia
Leucemia Linfocítica Crônica de Células B/patologia
Varicela/patologia
Dermatopatias Virais/patologia
Infiltração Leucêmica/patologia
-Imuno-Histoquímica
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Varicela/tratamento farmacológico
Resultado do Tratamento
Dermatopatias Virais/tratamento farmacológico
Infiltração Leucêmica/tratamento farmacológico
Derme/patologia
Herpes Zoster/patologia
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  10 / 151 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Rego, Eduardo Magalhäes
Texto completo
Texto completo
Id: biblio-898932
Autor: Furtado, Felipe Magalhães; Scheucher, Priscila Santos; Santana, Bárbara Amélia; Zanette, Dalila Lucíola; Calado, Rodrigo do Tocantins; Rego, Eduardo Magalhães; Matos, Daniel Mazza; Falcão, Roberto Passetto.
Título: Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia
Fonte: Rev. bras. hematol. hemoter;39(3):237-243, July-Sept. 2017. tab, graf.
Idioma: en.
Projeto: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.
Resumo: Abstract Background Evidence suggests that monoclonal B-cell lymphocytosis precedes all chronic lymphocytic leukemia cases, although the molecular mechanisms responsible for disease progression are not understood. Aberrant miRNA expression may contribute to the pathogenesis of chronic lymphocytic leukemia. The objective of this study was to compare miRNA expression profiles of patients with Binet A chronic lymphocytic leukemia with those of subjects with high-count monoclonal B-cell lymphocytosis and healthy volunteers (controls). Methods Twenty-one chronic lymphocytic leukemia patients, 12 subjects with monoclonal B-cell lymphocytosis and ten healthy volunteers were enrolled in this study. Flow cytometry CD19+CD5+-based cell sorting was performed for the chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis groups and CD19+ cells were sorted to analyze the control group. The expressions of miRNAs (miR-15a, miR-16-1, miR-29b, miR-34a, miR-181a, miR-181b and miR-155) were determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Results Significant differences between the expressions in the chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis groups were restricted to the expression of miR-155, which was higher in the former group. A comparison between healthy controls and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia patients revealed higher miR-155 and miR-34a levels and lower miR-15a, miR-16-1, miR-181a and miR-181b in the latter group. Conclusions Our results show a progressive increase of miR-155 expression from controls to monoclonal B-cell lymphocytosis to chronic lymphocytic leukemia. The role of miR-155 in the development of overt chronic lymphocytic leukemia in individuals with monoclonal B-cell lymphocytosis must be further analyzed.
Descritores: Teste de Stanford-Binet
Linfócitos B
Leucemia Linfocítica Crônica de Células B
MicroRNAs
Linfocitose
Limites: Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM



página 1 de 16 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde